uniQure

Questex LLC | November 15, 2018

UniQure has posted eagerly-anticipated data on the modified hemophilia B gene therapy it plans to take into phase 3. The FIX-Padua variant therapy achieved factor IX (FIX) activity levels of 23% to 37%, suggesting it is several times more effective than the version uniQure tested in earlier-phase trials. Throughout the development of its earlier, wild-type FIX gene therapy AMT-060, uniQure suffered as a result of unfavorable comparisons to Spark Therapeutics’ rival FIX Padua candidate SPK-...

fiercebiotech | June 17, 2019

Gene therapy specialist uniQure is considering selling up amid interest from large pharma buyers, according to Bloomberg. The report follows the revitalization of uniQure’s hemophilia B prospect and accompanying triple-digit stock price surge. According to unnamed sources, uniQure is working with advisers to assess options including a sale or partnership but is yet to decide which path to take. The report is credible given interest in the sort of assets and infrastructure uniQure possesses...

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...